Q2 Topics (1/2)

As of July 24, 2025

Launched	**Evrysdi**	Addition of dosage form (tablet)	May 2025 (Japan)
Approved	**AVMAPKI™***	Adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy (combination with FAK inhibitor FAKZYNJA™ (defactinib tablet))	May 2025 (U.S.)
	Elevidys	Duchenne muscular dystrophy (ambulatory) (gene therapy product)	May 2025 (Japan)
	PiaSky	Paroxysmal nocturnal hemoglobinuria	May 2025 (Taiwan)
	Vabysmo	Angioid streaks (additional indication)	May 2025 (Japan)
Filed	**Lunsumio + Polivy**	Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (additional indication)	May 2025 (Japan)
	Tecentriq	Unresectable thymic carcinoma (additional indication)	May 2025 (Japan)
	Alecensa	*ALK* fusion / rearrangement gene-positive unresectable advanced or recurrent solid tumors (additional indication)	June 2025 (Japan)
Initiation of Study	**GYM329**	Obesity (Phase II)	May 2025
	Vabysmo	Non-proliferative diabetic retinopathy (domestic Phase III)	May 2025
	Hemlibra	von Willebrand disease (Phase III)	June 2025
	AUBE00	Solid tumors (pan-KRAS inhibitor / mid-size molecule / oral) (Phase I)	June 2025
	RG6114/inavolisib	*PIK3CA*-mutated breast cancer (domestic Phase I/II)	July 2025

Orange: in-house projects (development in global) Blue: In-licensed from Roche (development and distribution in Japan) *Conducted by Verastem Oncology, a global licensee

Q2 Topics (2/2)

As of July 24, 2025

Readout	**Tecentriq + Avastin**	Phase III TALENTACE study (unresectable hepatocellular carcinoma) : Met one of the primary endpoints (TACE PFS)	May 2025
	AVMAPKI™*	Phase II RAMP 205 study (pancreatic ductal adenocarcinoma): Positive results for safety and efficacy	May 2025
Conclusion of Agreement	**Joint Research and License Agreement**	Development of novel therapies for age-related diseases with Gero	July 2025
Removed from Pipeline	**tiragolumab**	Esophageal cancer (SKYSCRAPER-07 study): Discontinuation of development	
	Five early-stage in-house products	Discontinuation of in-house development: LUNA18, SAIL66, SOF10, STA551, AMY109	
Medical Conference	**AVMAPKI™***	Phase II RAMP 205 study (pancreatic ductal adenocarcinoma (1st-line treatment), in combination with standard of care)	June 2025
	NEMLUVIO®**	Phase III ARCADIA long-term extension study (atopic dermatitis, 2-year data)	June 2025
	NEMLUVIO®**	Phase III OLYMPIA long-term extension study (prurigo nodularis, 2-year data)	June 2025
	NXT007	Phase I/II NXTAGE study (hemophilia A)	June 2025
	orforglipron***	Phase III ACHIEVE-1 study (type 2 diabetes)	June 2025
	Lunsumio + Polivy	Phase III SUNMO study (relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma)	June 2025
Open Innovation	**Investment by Chugai Venture Fund, LLC********	- Stylus Medicine - Two U.S.-based companies	April 2025 May and July 2025

Orange: in-house projects (development in global) Blue: In-licensed from Roche (development and distribution in Japan) TACE: transarterial chemoembolization, PFS: progression-free survival

*Conducted by Verastem Oncology, a global licensee **Conducted by Galderma, an overseas licensee *** Conducted by Eli Lilly and Company, a global licensee

****A cumulative total of 6 companies

2025: Key R&D Milestones

As of July 24, 2025

	Product	Indication / Study name	Progress
Projects to be Approved	Elevydis	Duchenne muscular dystrophy (ambulatory)	Approved
	Vabysmo	angioid streaks	Approved
P3/Pivotal Readouts	PiaSky	COMMUTE-a study*: atypical hemolytic uremic syndrome (aHUS)	
	Lunsumio + Polivy	SUNMO study: r/r aggressive B-cell non-Hodgkin's lymphoma	Achieved PE
	Lunsumio	CELESTIMO study: follicular lymphoma (2nd line)	
	giredestrant	persevERA study: HR positive breast cancer (1st line)	
		evERA study: HR positive breast cancer (1st line to 3rd line)	
	vamikibart	SANDCAT study: noninfectious uvetic macular edema (UME)	
	GAZYVA	INShore study: pediatric nephrotic syndrome	
P2 Readouts	GYM329 + Evrysdi	MANATEE study: spinal muscular atrophy (SMA)	
	GYM329	MANOEUVRE study: facioscapulohumeral muscular dystrophy (FSHD)	
	NXT007	hemophilia A	PoC confirmed / Decision to proceed to Phase III**
P1/2 Readout	trontinemab	Brainshuttle™ AD study: Alzheimer's disease	Decision to proceed to Phase III
Initiation of study	GYM329	obesity (Phase II study)	Study initiated

Orange: in-house projects (development in global) Blue: In-licensed from Roche (development and distribution in Japan) Underlined: Changes since April 24, 2025

*Adult/Adolescent patients, **Three phase 3 studies scheduled to initiate in 2026 (vs. FVIII products, vs. Hemlibra, and pediatric patients)

r/r: relapsed or refractory, PE: primary endpoint, HR: hormone receptor, PoC: Proof of Concept

NXT007: P1/2 Study for Severe Hemophilia A Without Inhibitors

- First clinical data of NXT007 in people with hemophilia A. Hemlibra-naïve people enrolled
- In the high dose cohorts (B-3, B-4), plasma concentrations reached the predicted normal range of FVIII–equivalent activity, with no treated bleeds observed. NXT007 was well tolerated, based on data up to date
- Three Phase III studies to be initiated in 2026, including H2H with Hemlibra. In addition to efficacy, safety including ADA (anti drug antibody) will be further evaluated

Efficacy (ABR : Annualized Bleeding Rate)

Mean ABR for treated bleeds *1



*1 Bleeding information before study was collected from 24 weeks before the study in a retrospective manner. ABR was calculated by annualizing the number of bleeding episodes observed during the evaluation period
*2 Dosing regimen was switched from 0.14 mg/kg Q2W to 0.28 mg/kg Q4W to reflect study protocol amendment

Saftey

- No dose-dependent increases in AEs were observed. No serious adverse events related to NXT007, or thromboembolic events were observed
- ADA was observed in 22 out of 30 patients; the number of ADA positive patients at the final observation before the data cutoff was 10. ADA impacting PK was observed in 2 patients. No ADA cross-reacting with emicizumab was observed

	B-1 (N=10)	B-2 (N=6)	B-3 (N=6)	B-4 (N=8)	Total (N=30)
ADA post-baseline incidence *3	**7**	**6**	**4**	**5**	**22**
ADA impacting PK	1	0	1	0	2
ADA cross-reacting with emicizumab	0	0	0	0	0

*3 No patients were ADA positive at baseline.

AUBE00 (Pan-KRAS Inhibitor)

- Second clinical-stage project applying mid-size molecule technology. Phase 1 trial initiated for solid tumors.
- Expecting superior efficacy compared to the pan-RAS inhibitor LUNA18, resulting from a wide therapeutic window based on KRAS-selective inhibitory activity.

Characteristics of AUBE00

- Expected to deliver anti-tumor effects and favorable safety profiles through selective inhibitory activity against KRAS-GDP
- Anticipated to target a wide range of KRAS genetic mutations. No such drugs have been approved yet, representing high unmet medical needs

What is KRAS ?

- One of the most frequently mutated oncogenes that contribute to tumor development and progression

Characteristics of mid-sized molecule technology

- Cyclic peptides containing non-natural amino acids
- Expected to improve binding affinity by interacting with broad interfaces of target proteins
- Possess high membrane permeability and metabolic stability, making oral administration feasible

GTP: guanosine triphosphate, GDP: guanosine diphosphate,
GAP: GTPase activating protein, GEF: guanine nucleotide exchange factor





Anti-tumor effects in a xenograft mouse model inoculated with a human KRAS-mutated non-small cell lung cancer (Source: Internal data)

AUBE00 demonstrated robust tumor regression in a xenograft model that was insensitive to a LUNA18 analog



Tumor growth inhibition (%):
This represents the tumor inhibition effect against tumor growth in the control group. 100% indicates tumor growth has completely stopped, while values exceeding 100% indicate tumor shrinkage

MTD (Maximal tolerable dose)

Reference：Nat Rev Drug Discov. 2014;13:828-51, modified

ROSE12: Anti-CTLA-4 Switch Antibody

- **ROSE12 is expected to have a wide therapeutic window, and its phase 1 trial for solid tumors is currently underway**

NK: natural killer
MΦ: macrophage
TME: tumor microenvironment

ROSE12:

- Selectively depletes immunosuppressive regulatory T cells (Tregs) in tumors and increases activated T cells, **demonstrating anti-tumor effects while reducing systemic side effects**
- Shows anti-tumor effects without increasing activated T cells in normal tissues in non-clinical studies
- A phase 1 clinical trial for patients with locally advanced or metastatic solid tumors as monotherapy and in combination with Tecentriq is ongoing in Japan and the U.S. (NCT05907980)

CTLA-4:

- Membrane protein highly expressed on Treg which has strong immunosuppressive function
- ROSE12 binds to Treg via CTLA-4 only in the presence of the switch molecule (extracellular ATP)



Source: The Society for Immunotherapy of Cancer 2024 poster presentation material (modified)

Portfolio of Each Modality

As of July 24, 2025

Drug Discovery	Pre-clinical development	Clinical	Launched

Antibody drugs, cellular and gene therapy products



26

NXT007
DONQ52
RAY121
GC33
ALPS12
ROSE12
BRY10

Enspryng
(MOGAD, AIE, TED/P3
DMD/P2)

PiaSky
(aHUS/P3, SCD/P2)

GYM329
(SMA/P2/3, FSHD/P2, Obesity/P2)

Actemra

Hemlibra

Enspryng

PiaSky

Developments licensed out to 3rd parties excl. Roche

Mitchga (JPN)
NEMLUVIO (U.S./EU)

Small molecule drugs



>9

REVN24

MINT91



Alecensa
(Maintenance treatment of
NSCLC(stage Ⅲ)
after chemoradiotherapy/P3)

Alecensa

Edirol

Oxarol

Developments licensed out to 3rd parties excl. Roche



AP306
(Hyperphosp
hatemia/P2)

orforglipron
(T2D, Obesity, Obstructive
sleep apnea/P3)



AVMAPKI
(NSCLC, mPDAC/P1/2)



Deberza



AVMAPKI
(LGSOC)

Mid-size molecule drugs

25



AUBE00

Blue: Joint development with Roche

Overview of Development Pipeline

Projected Submissions (Phase II & Later Programs and Products)

As of July 24, 2025

Filed

- TECENTRIQ (RG7446) r/r ENKL
- LUNSUMIO+ POLIVY (RG7828+RG7596) r/r aNHL ★
- CELLCEPT Refractory nephrotic syndrome
- ALECENSA (AF802/RG7853) *ALK* fusion / rearrangement gene-positive unresectable advanced or recurrent solid tumors ★
- TECENTRIQ (RG7446) Unresectable thymic carcinoma ★

NME Line extension

In-house

In-licensed (Roche)

★ new entry

aHUS: atypical hemolytic uremic syndrome
r/r aNHL: relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
DMD: Duchenne muscular dystrophy
r/r ENKL: relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type
FSHD: facioscapulohumeral muscular dystrophy
HCC: hepatocellular carcinoma
LBCL: large B-cell lymphoma
MIBC: muscle-invasive bladder cancer
MOGAD: myelin oligodendrocyte glycoprotein antibody–associated disease
NSCLC: non-small cell lung cancer
nAMD: neovascular age-related macular degeneration
SCD: sickle cell disease
SMA: spinal muscular atrophy

2025

- TECENTRIQ+AVASTIN (RG7446+RG435) HCC (intermediate stage)
- TECENTRIQ (RG7446) MIBC (adj)
- tiragolumab+ TECENTRIQ (RG6058+RG7446) NSCLC (Stage III)

2026

- tiragolumab(RG6058) 1L HCC TECENTRIQ+AVASTIN
- ranibizumab(PDS) (RG6321) nAMD
- ENSPRYNG (SA237/RG6168) Thyroid eye disease
- vamikibart (RG6179) UME
- PIASKY (SKY59/RG6107) aHUS
- giredestrant (RG6171) 1L-3L Breast cancer
- ENSPRYNG (SA237/RG6168) MOGAD
- giredestrant (RG6171) 1L Breast cancer
- GAZYVA(RG7159) Pediatric nephrotic syndrome
- GAZYVA (RG7159) Lupus nephritis
- LUNSUMIO (RG7828) 2L Follicular lymphoma
- TECENTRIQ (RG7446) NSCLC (perioperative)
- ranibizumab(PDS) (RG6321) DME

2027

- GAZYVA (RG7159) Extra renal lupus
- ELEVYDIS(RG6356) DMD (non-ambulatory)
- afimkibart (RG6631) Ulcerative colitis
- divarasib (RG6330) 2L NSCLC
- giredestrant (RG6171) Breast cancer (adj)
- ENSPRYNG (SA237/RG6168) Autoimmune encephalitis

2028 and beyond

- ENSPRYNG (SA237/RG6168) DMD
- NXT007/RG6512 Hemophilia A
- GYM329/RG6237 Obesity ★
- GYM329/RG6237 FSHD
- GYM329/RG6237 SMA + EVRYSDI
- VABYSMO (RG7716) Non-proliferative diabetic retinopathy ★
- LUNSUMIO (RG7828) Previously untreated Follicular lymphoma
- sefaxersen (RG6299) IgA nephropathy
- glofitamab (RG6026) Previously untreated LBCL + Polivy
- PIASKY (SKY59/RG6107) SCD (Global (excluding Japan))

Overview of Development Pipeline

Projects under Development （1/2）

As of July 24, 2025

	Phase I	Phase II	Phase III	Filed
Cancer	**GC33 / codrituzumab** - HCC **ALPS12 / clesitamig** - Solid tumors **ROSE12** - Solid tumors **MINT91** - Solid tumors **AUBE00** - Solid tumors★ **RG7421 / cobimetinib** - Solid tumors **RG6026 / glofitamab** - Hematologic tumors **RG6160 / cevostamab** - r/r MM	**RG6114 / inavolisib** - *PIK3CA*-mutated breast cancer (PI/II) ★	**AF802 (RG7853) / Alecensa** - NSCLC (stage III)* **RG7446 / Tecentriq** - NSCLC (perioperative) - MIBC (adjuvant) - HCC (2L) **RG7446 / Tecentriq +RG435 / Avastin** - HCC (intermediate stage) **RG6058 / tiragolumab +RG7446 / Tecentriq** - NSCLC (stage III) **RG6058 / tiragolumab+RG7446 / Tecentriq+RG435 / Avastin** - HCC (1L) **RG6171 /giredestrant** - BC (adjuvant) - BC (1L) - BC (1L- 3 L) **RG7828 / Lunsumio** - Follicular lymphoma (2L) - Previously untreated follicular lymphoma **RG6026 / glofitamab +RG7596 / Polivy** - Previously untreated large B-cell lymphoma **RG6330 / divarasib** - NSCLC (2L)	**AF802 (RG7853) / Alecensa** - *ALK* fusion / rearrangement gene-positive unresectable advanced or recurrent solid tumors★ **RG7446 / Tecentriq** - r/r ENKL - Unresectable thymic carcinoma★ **RG7828 / Lunsumio +RG7596 / Polivy** - r/r aNHL ★
Immunology	**DONQ52** - Celiac disease **RAY121** - Autoimmune disease		**RG7159 / Gazyva** - Lupus nephritis - Pediatric nephrotic syndrome - Extra renal lupus **RG6299 / sefaxersen** -IgA nephropathy **RG6631 / afimkibart** - Ulcerative colitis	**CellCept** - Refractory nephrotic syndrome

Orange: in-house projects (development in global)　Blue: In-licensed from Roche (development and distribution in Japan　★: Projects with advances in stages since April 24, 2025

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies. *maintenance therapy after chemoradiation

aNHL: aggressive B-cell non-Hodgkin's lymphoma, BC: breast cancer, ENKL: refractory extranodal natural killer/T-cell lymphoma, nasal type, HCC: hepatocellular carcinoma, MIBC: muscle-invasive bladder cancer, MM: multiple myeloma, NSCLC: non-small cell lung cancer, r/r: relapsed or refractory

Projects under Development (2/2)

As of July 24, 2025

	Phase I	Phase II	Phase III	Filed
Neurology	**RG7935 / prasinezumab** - Parkinson's disease **RG6102/trontinemab** -Alzheimer's disease (PI/II)	**GYM329 (RG6237) / emugrobart** - SMA (combination with Evrysdi) (PII/III) - FSHD **SA237 (RG6168) / Enspryng** - DMD **RG6042 / tominersen** - Huntington's disease	**SA237 (RG6168) / Enspryng** - MOGAD - AIE **RG6356 / Elevydis** - DMD* (non-ambulatory)	
Hematology		**SKY59 (RG6107) / PiaSky(Global (excluding Japan))** - SCD **NXT007 (RG6512)** - Hemophilia A (PI/II)	**SKY59 (RG6107) / PiaSky** - aHUS **ACE910 (RG6013) / Hemlibra** - von Willebrand disease★	
Ophthalmology	**RG6321 / PDS** - nAMD (PI/II) - DME (PI/II)		**SA237 (RG6168) / Enspryng** - TED **RG6179 / vamikibart** - UME **RG7716 / Vabysmo** - Non-proliferative diabetic retinopathy★	
Other	**REVN24** - Acute diseases **BRY10** - Chronic diseases **RAY121** - (Not disclosed) **RG6615 / zilebesiran** - Hypertension (PI/II)	**GYM329 (RG6237) / emugrobart** - Obesity★		

Orange: in-house projects (development in global) Blue: In-licensed from Roche (development and distribution in Japan)
In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies

★: Projects with advances in stages since April 24, 2025
*Sarepta manages the global study, including Japan.

aHUS: atypical hemolytic uremic syndrome, AIE: autoimmune encephalitis, DMD: Duchenne muscular dystrophy, DME: diabetic macular edema, FSHD: facioscapulohumeral muscular dystrophy, MOGAD: myelin oligodendrocyte glycoprotein antibody–associated disease, nAMD: neovascular age-related macular degeneration, SCD: sickle cell disease, SMA: spinal muscular atrophy, TED: thyroid eye disease, UME: uvetic macular edema

Advance Hemlibra into Global PhIII Development for von Willebrand Disease (VWD)

Hemlibra is expected to prevent bleeds for people with Type 3 VWD due to its mode of action

- von Willebrand factor (VWF) is a plasma protein that mediates platelet adhesion and aggregation at sites of vascular injury and also binds and stabilizes the blood clotting factor VIII (FVIII) in the circulation
- VWD is an inherited bleeding disorder caused by quantitative deficiency, dysfunction, or absence of VWF (Type 1, 2, and 3 respectively), characterized mainly by mucosa-associated bleeding (e.g. nose bleeds, oral-cavity bleeds, easy bruising) and heavy menstrual periods
- FVIII mimetic function of Hemlibra is expected to prevent the bleeds for people with Type 3 VWD, who can experience bleeding in joints and muscle due to reduction in FVIII activity caused by VWF absence.
  - ✓ Current replacement therapy with VWF has several issues: i.v. infusion, frequent injection due to short half life, development of alloantibody





Kitazawa et al, Nature Medicine, 2012 Oct;18(10):1570-4

Oldenburg J, et al, N Engl J Med. 2017

Small Molecule Drug Discovery: Portfolio

As of July 24, 2025

In-house molecule



Chronic disease >7
Cancer >1

- **MINT91** (Solid tumors/ P1)
- **REVN24** (Acute disease/P1)
- **Alecensa** (Maintenance treatment of NSCLC(stage III) after chemoradiotherapy /P3)
- **Alecensa** (NSCLC, NSCLC adjuvant)
- **Edirol** (Osteoporosis)
- **Oxarol** (Psoriasis)

Developments licensed out to 3rd parties excl. Roche

- **AP306** (Hyperphosphatemia /P2)
- **orforglipron** (T2D,Obesity, Obstructive sleep apnea/P3)
- **Deberza** (T2D)
- **AVMAPKI** (NSCLC, mPDAC/P1/2)
- **AVMAPKI** (LGSOC)

Drug Discovery | Pre-clinical development | Clinical | Launched

Mid-Size Molecule Drug Discovery: Portfolio

As of July 24, 2025



Overview of Development Pipeline

Antibody Drug, Cellular and Gene Therapy: Portfolio

As of July 24, 2025

Established technologies



Infectious disease

- NXT007 (Hemophilia A/P1/2)
- RAY121(Auto-immune disease/P1)
- GC33 (Cancer/P1)
- BRY10 (Chronic disease/P1)
- Enspryng (MOGAD, AIE, TED/P3, DMD/P2)
- PiaSky (aHUS/P3, SCD/P2)
- GYM329 (SMA/P2/3, FSHD/P2, Obesity/P2)
- Actemra (Rheumatoid arthritis etc.)
- Hemlibra (Hemophilia A etc.)
- Enspryng (NMOSD)
- PiaSky (PNH)

Developments licensed out to 3rd parties excl. Roche

- Mitchga (Atopic dermatitis/JPN)
- NEMLUVIO (Atopic dermatitis, PN (U.S./EU))

New technologies



- DONQ52 (Celiac/P1)
- ALPS12 (Cancer/P1)
- ROSE12 (Cancer/P1)

Drug Discovery | Pre-clinical development | Clinical | Launched

Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2)

As of July 24, 2025

Generic name/ Development code	Mode of Action	Licensee	Granted rights to licensee	Indication	Stage	Progress
avutometinib /VS-6766	RAF/MEK clamp	Verastem Oncology	Exclusive global license for the manufacturing, development and marketing	*KRAS*-mutated recurrent low-grade serous ovarian cancer (LGSOC)	Overseas/US: P3 US: Approved ★	● U.S. FDA BTD (recurrent LGSOC in combination with defactinib) ● U.S. orphan drug designation (avutometinib in combination with defactinib in recurrent LGSOC) ● RAMP301 trial (P3) ongoing globally ● Obtained approval in May 2025 under the accelerated approval pathway in the U.S. for the treatment of adult patients with *KRAS*-mutated recurrent LGSOC who have received prior systemic therapy, in combination with defactinib ★
					Japan: P2	● RAMP201J trial (P2 in combination with defactinib) ongoing
				Advanced *KRAS G12C* mutant non-small cell lung cancer （NSCLC）	Overseas/ U.S. : P1/2	● RAMP 203 trial (P1/2 in combination with sotorasib with or without defactinib) ongoing globally ● U.S. FDA fast track designation of avutometinib in combination with sotorasib ● U.S. FDA fast track designation for the combination of avutometinib plus defactinib with sotorasib
				First-line metastatic pancreatic ductal adenocarcinoma (mPDAC)	US: P1/2	● RAMP 205 trial (P1/2 evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel) ongoing

★: Changes since April 24, 2025

Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2)

As of July 24, 2025

Generic name/ Development code	Mode of Action	Licensee	Granted rights to licensee	Indication	Stage	Progress
nemolizumab	Anti-IL-31 receptor A humanized monoclonal antibody	Galderma	Exclusive global license for the development and marketing excluding Japan	**Atopic dermatitis**	Overseas: Approved (US/EU)	● Obtained U.S. FDA approval in Dec 2024 ● Obtained EMA approval in Feb 2025
				Prurigo nodularis	Overseas: Approved (US/EU)	● Obtained U.S. FDA approval in Aug 2024 ● Obtained EMA approval in Feb 2025
orforglipron /LY3502970	Oral non-peptidic GLP-1 receptor agonist	Eli Lilly and Company	Worldwide development and commercialization rights	Type 2 diabetes	Global: P3	● Phase 3 (ACHIEVE-1): orforglipron demonstrated HbA1c reduction by an average of 1.3% to 1.6% and a 7.9% weight reduction at the highest dose at 40 weeks. A safety profile was consistent with injectable GLP-1 medicines
				Obesity	Global: P3	● Phase 2 study: orforglipron demonstrated up to a 14.7% weight reduction at 36 weeks. The results were published in the New England Journal of Medicine*
				Obstructive sleep apnea	Global: P3	● Initiated a phase 3 study in Q4 2024
-/AP306 (EOS789)	Oral inhibitor of phosphate transporters	Alebund	Exclusive global license for the manufacturing, development and marketing	Hyperphosphatemia	China: P2	● In a phase 2 study, AP306 showed a clinically significant reduction in serum phosphorus levels at the end of treatment compared to baseline ● AP306 is granted China Breakthrough Therapy Designation for the treatment of hyperphosphatemia in patients with chronic kidney disease

* Sean W, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. *NEJM* 2023.

FoundationOne CDx Cancer Genomic Profile -Companion diagnostic indications-

As of July 24, 2025

Alterations	Cancer type	Relevant drugs
Activating *EGFR* alterations	Non-small cell lung cancer (NSCLC)	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate
EGFR exon 20 T790M alteration		osimertinib mesilate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib, brigatinib
ROS1 fusion genes		Entrectinib
MET exon 14 skipping alterations		capmatinib hydrochloride hydrate
BRAF V600E and V600K alterations	Malignant melanoma	dabrafenib mesylate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib
ERBB2 2 copy number alterations (HER2 gene amplification positive)	BC	trastuzumab (genetical recombination)
AKT1 alterations		capivasertib
PIK3CA alterations		
PTEN alterations		
KRAS/NRAS wild type	CRC	cetuximab (genetical recombination), panitumumab (genetical recombination)
Microsatellite Instability-High		nivolumab (genetical recombination)
Microsatellite Instability-High	Solid tumors	pembrolizumab (genetical recombination)
Tumor Mutational Burden-High		pembrolizumab (genetical recombination)
NTRK1/2/3 fusion genes		entrectinib, larotrectinib sulfate, repotrectinib
RET fusion genes		selpercatinib
BRCA1/2 alterations	Ovarian cancer	olaparib
BRCA1/2 alterations	Prostate cancer	olaparib, talazoparib tosilate
FGFR2 fusion genes	Biliary tract cancer	pemigatinib

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval

FoundationOne Liquid CDx Cancer Genomic Profile

-Companion diagnostic indications-

As of July 24, 2025

Alterations	Cancer type	Relevant drugs
Activating *EGFR* alterations	Non-small cell lung cancer (NSCLC)	afatinib maleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate
EGFR exon 20 T790M alteration		osimertinib mesilate
ALK fusion genes		alectinib hydrochloride, crizotinib, ceritinib
ROS1 fusion genes		entrectinib
MET exon14 skipping alterations		capmatinib hydrochloride hydrate
NTRK1/2/3 fusion genes	Solid tumors	entrectinib
BRCA1/2 alterations	Prostate cancer	olaparib